Larvol Delta - Acumen-Pharmaceuticals-Announces-First-Participant-Dosed-in-Phase-2-OpenLabel-Extension-Study-of-Sabirnetug-in-People-with-Early-Alzheimers-Disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.globenewswire.com/news-release/2025/11/17/3189097/0/en/Acumen-Pharmaceuticals-Announces-First-Participant-Dosed-in-Phase-2-Open-Label-Extension-Study-of-Sabirnetug-in-People-with-Early-Alzheimer-s-Disease.html

Nov 17, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next